WO2025158381 - METHODS FOR ENHANCING ADENO-ASSOCIATED VIRUS (AAV) PRODUCTION
National phase entry is expected:
Publication Number
WO/2025/158381
Publication Date
31.07.2025
International Application No.
PCT/IB2025/050818
International Filing Date
24.01.2025
Title **
[English]
METHODS FOR ENHANCING ADENO-ASSOCIATED VIRUS (AAV) PRODUCTION
[French]
PROCÉDÉS D'AMÉLIORATION DE LA PRODUCTION DE VIRUS ADÉNO-ASSOCIÉ (AAV)
Applicants **
SANOFI
Inventors
LI, Qingliang
NIE, Yingchao
PAN, Hao
Priority Data
24305146.3
26.01.2024
EP
63/644,013
08.05.2024
US
63/713,654
30.10.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4254 | |
| EPO | Filing, Examination, Granting | 47570 | |
| Japan | Filing, Examination, Granting | 3696 | |
| South Korea | Filing, Examination, Granting | 5263 | |
| USA | Filing, Examination, Granting | 16590 |
Total:
77,373
Contact Us
Abstract[English]
Compositions, systems, and methods for enhancing adenovirus L4 region 33K protein (Ad L4-33K) expression in an AAV producing cell are disclosed. For example, a system for AAV production including (a) a first nucleic acid molecule encoding an adenovirus L4-33K protein; and (b) a second nucleic acid molecule comprising adenovirus genes E2A, L4, E4, and VA RNA is described.[French]
L'invention concerne des compositions, des systèmes et des procédés pour améliorer l'expression de la protéine 33K de région L4 d'adénovirus (Ad L4-33K) dans une cellule de production d'AAV. Par exemple, l'invention concerne un système de production d'AAV comprenant (a) une première molécule d'acide nucléique codant pour une protéine L4-33 K d'adénovirus ; et (b) une seconde molécule d'acide nucléique comprenant des gènes d'adénovirus E2A, L4, E4 et un ARN VA.